Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...
A new trial finds that cetuximab outperforms durvalumab as a second-line treatment in patients who cannot tolerate cisplatin.
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...
AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
The FDA has approved Imfinzi (durvalumab) to treat LS-SCLC that has not progressed after concurrent platinum-based chemotherapy and radiation.
Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...
The government had issued notifications to reduce basic customs duty (BCD) to zero on these three drugs/formulations, apart ...
The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer ...